Form 483

Eisai Company Ltd. Form 483, 2018-12-21

FDA issued a Form 483 to Eisai Company Ltd. on 2018-12-21 with 7 public-safe observations.

483· Form 483 issuedHuman Drugs7 observations

Eisai Company Ltd. · Kakamigahara, Japan · Issued December 21, 2018

Overview

  • 7 public-safe observations are available for this inspection.
  • 7 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

21 Dec 2018
21 CFR 211.160(a)

Following/documenting laboratory controls

Cited by Saied A Asbagh

21 Dec 2018
21 CFR 211.180(c)

Records not made readily available to FDA

Cited by Saied A Asbagh

21 Dec 2018
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by Saied A Asbagh

21 Dec 2018
21 CFR 211.67(b)

Written procedures fail to include

Cited by Saied A Asbagh

21 Dec 2018
21 CFR 211.68(a)

Calibration/Inspection/Checking not done

Cited by Saied A Asbagh

Inspected site

ECEisai Company Ltd.Kakamigahara, Japan

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.111Cited across public-safe Form 483 observations1x
21 CFR 211.160(a)Cited across public-safe Form 483 observations1x
21 CFR 211.180(c)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x
21 CFR 211.68(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 7 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere